Back to Trials
NCT07348237PHASE1RecruitingAccepts Healthy Volunteers

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

Merck Sharp & Dohme LLC

Start Date

3/2/2026

Completion Date

8/18/2026

Summary

The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.

Eligibility Criteria

Age Range: 24 years to 85 years

The main inclusion criteria include but are not limited to the following: * Is in generally good health, with the exception of renal impairment participants. Participants with stable, chronic medical or psychiatric conditions may be included at the discretion of the investigator and the Sponsor. Severe Renal Impairment Participants: * Has an estimated glomerular filtration rate (eGFR) \< 30 mL/min), but is not on hemodialysis (HD) ESRD on HD Participants: * Has ESRD maintained on stable outpatient regimen of intermittent high-flux HD at a healthcare center for \> 3 months prior to study entry The main exclusion criteria include but are not limited to the following: Renal Impairment Participants: * History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. Healthy Matched Control Participants: * History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.

Interventions

DRUG

MK-2828

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Chronic Kidney FailureEnd-Stage Renal DiseaseRenal Impairment

Locations

Panax Clinical Research ( Site 0003)

Miami Lakes, Florida 33014

United States

Floridian Clinical Research ( Site 0001)

Miami Lakes, Florida 33016

United States

Orlando Clinical Research Center ( Site 0002)

Orlando, Florida 32809

United States